1. A previously healthy traveler returns from a region where chloroquine-resistant Plasmodium falciparum predominates and is diagnosed with uncomplicated falciparum malaria. The patient is alert, tolerating oral intake, and has no signs of severe disease. Integrating species lethality, regional resistance, and agent selection, what is the most appropriate treatment?
A) Oral chloroquine monotherapy, because the patient has no severe features
B) Observation with antipyretics, because uncomplicated falciparum resolves without antimalarials
C) An oral artemisinin-based combination therapy (ACT), such as artemether-lumefantrine, because falciparum is potentially lethal and the strain is chloroquine-resistant
D) Oral primaquine monotherapy, to eradicate any liver-stage parasites
E) A single oral dose of an artemisinin derivative alone, because artemisinins clear parasites rapidly
ANSWER: C
Rationale:
This question integrates three concepts: falciparum is the most lethal species and must be treated promptly; the strain is chloroquine-resistant; and uncomplicated disease in a patient tolerating oral intake is treated with an oral regimen. The correct choice is an oral ACT such as artemether-lumefantrine, the recommended first-line treatment for uncomplicated chloroquine-resistant falciparum malaria. This is correct.
Option A: Option A is incorrect because chloroquine monotherapy will fail against a chloroquine-resistant strain regardless of disease severity.
Option B: Option B is incorrect because falciparum malaria is potentially fatal and is never managed by observation alone.
Option D: Option D is incorrect because primaquine is an 8-aminoquinoline used for radical cure and transmission blocking; falciparum does not form hypnozoites and primaquine is not the treatment for the acute blood-stage infection.
Option E: Option E is incorrect because an artemisinin given alone, without a partner drug, is inadequate therapy and selects for resistance, which is the entire rationale for combination therapy.
2. A patient is diagnosed with Plasmodium vivax malaria. The clinician plans both to treat the acute illness and to prevent future relapse. Integrating the biology of relapse with the pharmacogenetic safety requirement, which plan is correct?
A) Treat the acute blood-stage infection with an appropriate blood schizonticide, and add a terminal 8-aminoquinoline (primaquine or tafenoquine) for radical cure only after confirming the patient is not G6PD deficient by quantitative testing
B) Give primaquine alone, because it treats both the blood stage and the liver stage and needs no pretreatment testing
C) Treat the acute infection with a blood schizonticide and stop, because vivax does not relapse
D) Add the 8-aminoquinoline first and obtain the G6PD test afterward, since hemolysis is easily reversed
E) Use long-term suppressive chloroquine indefinitely instead of radical cure
ANSWER: A
Rationale:
This question integrates relapse biology (vivax forms dormant liver hypnozoites that blood schizonticides cannot reach) with the pharmacogenetic safety requirement (8-aminoquinolines cause dose-dependent hemolysis in G6PD deficiency). Complete management is therefore a blood schizonticide for the acute infection plus a terminal 8-aminoquinoline for radical cure, given only after quantitative G6PD testing confirms the patient can tolerate it. This is correct.
Option B: Option B is incorrect because primaquine is not a reliable treatment for the acute blood-stage illness and must never be given before G6PD status is known.
Option C: Option C is incorrect because vivax does relapse from hypnozoites, so stopping after blood-stage treatment leaves the relapse reservoir intact.
Option D: Option D is incorrect because the G6PD test must precede the 8-aminoquinoline; hemolysis in severe deficiency can be life-threatening, not trivially reversible.
Option E: Option E is incorrect because indefinite suppressive chloroquine does not eradicate hypnozoites and is not the correct approach to relapse prevention.
3. A patient with Plasmodium falciparum malaria presents with impaired consciousness, a high parasite density, and metabolic acidosis. Integrating severity assessment with parenteral agent selection, what is the most appropriate immediate treatment?
A) Oral artemether-lumefantrine, because it is the first-line ACT for falciparum
B) Intravenous artesunate, because the patient meets criteria for severe malaria and intravenous artesunate is the first-line treatment, reducing mortality compared with intravenous quinine
C) Oral chloroquine, because intravenous access is unnecessary in malaria
D) Subcutaneous primaquine, to provide rapid liver-stage and blood-stage coverage
E) Oral atovaquone-proguanil, because its causal action treats severe disease fastest
ANSWER: B
Rationale:
This question integrates two concepts: recognizing severe malaria (impaired consciousness, high parasitemia, acidosis are severity criteria) and selecting the correct parenteral agent. Severe malaria requires intravenous artesunate, which is first-line and reduces mortality relative to intravenous quinine. This is correct.
Option A: Option A is incorrect because a patient with severe disease and impaired consciousness should not be managed with an oral regimen, which may not be absorbed and is too slow.
Option C: Option C is incorrect because chloroquine is inappropriate for severe falciparum disease (resistance and inadequate efficacy) and oral therapy is wrong for a severely ill patient.
Option D: Option D is incorrect because primaquine is an 8-aminoquinoline for radical cure and transmission blocking, not a treatment for acute severe malaria.
Option E: Option E is incorrect because atovaquone-proguanil is an oral causal prophylactic/treatment agent, not appropriate first-line therapy for severe disease requiring parenteral treatment.
4. A pregnant woman in her second trimester must travel to a region with chloroquine-resistant Plasmodium falciparum and asks about malaria prophylaxis. She has no psychiatric history. Integrating prophylaxis options with safety in pregnancy, which agent is the most appropriate choice?
A) Doxycycline, because tetracyclines are the preferred prophylaxis throughout pregnancy
B) Primaquine, because causal prophylaxis is safest for the fetus
C) Chloroquine, because resistance does not affect prophylactic efficacy
D) Mefloquine, because it is considered acceptable for prophylaxis in pregnancy and is effective in chloroquine-resistant areas, whereas the main alternatives are avoided in this setting
E) No prophylaxis, because all antimalarials are contraindicated in pregnancy
ANSWER: D
Rationale:
This question integrates prophylaxis selection for a chloroquine-resistant area with pregnancy safety. Mefloquine is regarded as acceptable for prophylaxis in pregnancy and is effective against chloroquine-resistant strains, and this patient has no psychiatric contraindication. The principal alternatives are problematic in pregnancy: doxycycline is avoided because tetracyclines affect fetal bone and teeth, and primaquine is avoided because the fetal G6PD status is unknown and hemolysis cannot be excluded. This is correct.
Option A: Option A is incorrect because doxycycline is avoided in pregnancy, not preferred.
Option B: Option B is incorrect because primaquine is avoided in pregnancy owing to the unknown fetal G6PD status and hemolysis risk.
Option C: Option C is incorrect because chloroquine would be ineffective against a chloroquine-resistant strain.
Option E: Option E is incorrect because effective and acceptable prophylaxis exists in pregnancy, and an unprotected pregnant traveler faces high risk from falciparum malaria.
5. In a particular region, surveillance shows that parasites have developed resistance to the long-acting partner drug used in the local artemisinin-based combination therapy, while the artemisinin component still clears parasites rapidly. Applying the pharmacokinetic logic of how an ACT protects against resistance, what is the predicted consequence?
A) Cure rates will fall, because once the partner drug fails, the rapidly eliminated artemisinin is left to act briefly and alone, allowing residual parasites to survive and recrudesce
B) Cure rates will rise, because partner-drug resistance forces the artemisinin to work harder
C) There will be no change, because the artemisinin component alone is fully curative
D) The artemisinin will compensate by extending its own half-life in response to partner-drug resistance
E) Resistance to the partner drug protects the artemisinin from being cleared, improving efficacy
ANSWER: A
Rationale:
This question applies the ACT design logic to a novel scenario. An ACT pairs a fast-acting but rapidly eliminated artemisinin with a long-acting partner drug; the partner drug remains present after the artemisinin is gone, clearing residual parasites and shielding the artemisinin from resistance selection. If the partner drug fails, that protective tail disappears: the short-lived artemisinin acts only briefly and effectively alone, residual parasites survive, and cure rates fall with recrudescence. This is correct.
Option B: Option B is incorrect because losing the partner drug does not enhance artemisinin activity; there is no compensatory mechanism.
Option C: Option C is incorrect because the artemisinin alone, given its short exposure, is not reliably curative, which is the reason combination therapy exists.
Option D: Option D is incorrect because a drug's half-life is a fixed pharmacokinetic property and does not adaptively lengthen in response to resistance.
Option E: Option E is incorrect because partner-drug resistance does not protect or potentiate the artemisinin; it removes the safety net.
6. A patient with confirmed Plasmodium vivax malaria has completed blood-stage treatment. Quantitative testing shows the patient is G6PD deficient. Integrating the relapse-prevention requirement with 8-aminoquinoline toxicity, which approach to radical cure is most appropriate?
A) Give standard daily primaquine at full dose immediately, since blood-stage treatment is complete
B) Give a single full dose of tafenoquine, because its long action is ideal in G6PD deficiency
C) Double the primaquine dose to overcome reduced red-cell defenses
D) Give standard tafenoquine plus prophylactic transfusion to offset hemolysis
E) Recognize that standard 8-aminoquinoline dosing risks severe hemolysis, avoid long-acting tafenoquine, and individualize the decision — for example a supervised intermittent (weekly) primaquine regimen with hemoglobin monitoring, weighing relapse risk against hemolysis risk
ANSWER: E
Rationale:
This question integrates the relapse-prevention requirement with 8-aminoquinoline oxidative toxicity in G6PD deficiency. Standard 8-aminoquinoline dosing risks severe hemolysis in a G6PD-deficient patient, so the radical-cure decision must be individualized rather than executed routinely. Long-acting tafenoquine is contraindicated because its prolonged action makes hemolysis severe and non-reversible; a recognized alternative is a supervised intermittent (weekly) primaquine regimen with hemoglobin monitoring, balancing relapse risk against hemolysis risk. This is correct.
Option A: Option A is incorrect because standard full-dose daily primaquine could cause dangerous hemolysis in this patient.
Option B: Option B is incorrect because tafenoquine is contraindicated in G6PD deficiency precisely because of its long, non-reversible hemolytic action.
Option C: Option C is incorrect and dangerous because increasing the dose increases oxidative hemolysis.
Option D: Option D is incorrect because routinely giving contraindicated tafenoquine and planning to transfuse around predictable hemolysis is not an accepted strategy.
7. A traveler with a documented history of major depression and a prior seizure plans a trip to a Southeast Asian region where both chloroquine resistance and mefloquine resistance are well established. Integrating regional resistance with the patient's contraindications, which prophylaxis is most appropriate?
A) Mefloquine, because weekly dosing is most convenient
B) Atovaquone-proguanil (or doxycycline), because chloroquine is excluded by resistance and mefloquine is excluded both by regional resistance and by the patient's psychiatric and seizure history
C) Chloroquine, because it is safe in psychiatric disease
D) No prophylaxis, because no safe option exists for this patient
E) Primaquine monotherapy as the sole prophylactic, ignoring G6PD status
ANSWER: B
Rationale:
This question integrates two constraints. Regional resistance excludes chloroquine (chloroquine-resistant) and also excludes mefloquine (mefloquine-resistant in this region), and the patient's psychiatric and seizure history independently contraindicates mefloquine because of its neuropsychiatric boxed warning. The appropriate remaining choices are atovaquone-proguanil or doxycycline, both effective in chloroquine- and mefloquine-resistant areas. This is correct.
Option A: Option A is incorrect because mefloquine is doubly excluded here, by regional resistance and by the psychiatric/seizure contraindication.
Option C: Option C is incorrect because chloroquine would be ineffective against the resistant strain regardless of psychiatric safety.
Option D: Option D is incorrect because effective options (atovaquone-proguanil, doxycycline) remain available.
Option E: Option E is incorrect because primaquine is not used as routine sole prophylaxis here and must never be given without G6PD testing.
8. A patient with uncomplicated falciparum malaria also has congenital long QT syndrome and a baseline prolonged QTc. Integrating antimalarial cardiac toxicity with treatment selection, which consideration should most guide the choice of therapy?
A) Quinine is the safest choice because it has no effect on cardiac conduction
B) Quinidine should be preferred because its antiarrhythmic action will shorten the QT interval
C) Agents with significant QT-prolonging potential — quinine, quinidine, and piperaquine-containing ACTs — warrant caution and ECG monitoring, and an agent with a more favorable QT profile (for example artemether-lumefantrine with monitoring, or avoiding the highest-risk agents) is preferred
D) No antimalarial affects the QT interval, so cardiac status is irrelevant
E) Halofantrine should be selected first because it is the least arrhythmogenic antimalarial
ANSWER: C
Rationale:
This question integrates antimalarial cardiac toxicity with drug selection. Several antimalarials prolong the QT interval — notably quinine and quinidine, and piperaquine-containing ACTs — so in a patient with long QT syndrome these agents warrant caution and ECG monitoring, with correction of electrolytes and preference for a regimen with a more favorable QT profile. This is correct.
Option A: Option A is incorrect because quinine does affect cardiac conduction and can prolong the QT interval.
Option B: Option B is incorrect because quinidine is strongly QT-prolonging (a class IA antiarrhythmic), not QT-shortening, and is dangerous here.
Option D: Option D is incorrect because several antimalarials do prolong the QT interval, so cardiac status is highly relevant.
Option E: Option E is incorrect because halofantrine is notably arrhythmogenic and markedly prolongs the QT interval, making it among the worst choices in long QT syndrome.
9. A patient treated with a full course of an artemisinin-based combination therapy for falciparum malaria acquired in the Greater Mekong region of Southeast Asia still has detectable parasitemia on blood smear at 72 hours, with an unusually slow fall in parasite count. Integrating the concept of delayed parasite clearance with ACT failure, what is the best interpretation and next step?
A) Suspect artemisinin partial resistance with possible partner-drug failure; reassess the regimen, treat as a treatment failure (for example with intravenous artesunate and an effective alternative partner drug), and send samples for resistance genotyping
B) Conclude the patient is cured, because any detectable parasitemia at 72 hours is normal
C) Conclude the diagnosis was wrong, because ACTs never fail
D) Immediately add chloroquine, because chloroquine reverses artemisinin resistance
E) Switch to oral primaquine monotherapy to clear the blood-stage parasites
ANSWER: A
Rationale:
This question integrates delayed parasite clearance with ACT failure. In the Greater Mekong region, artemisinin partial resistance (marked by slow parasite clearance) combined with partner-drug resistance produces genuine ACT treatment failure. Persistent parasitemia with slow clearance at 72 hours should prompt treating the episode as a failure — for example with intravenous artesunate and an effective alternative partner drug — and sending samples for resistance genotyping. This is correct.
Option B: Option B is incorrect because adequate response normally produces a marked fall in parasitemia by 72 hours; persistent slow-clearing parasitemia is abnormal.
Option C: Option C is incorrect because ACTs can and do fail where artemisinin and partner-drug resistance coexist.
Option D: Option D is incorrect because chloroquine does not reverse artemisinin resistance and has no role here.
Option E: Option E is incorrect because primaquine is not a treatment for acute blood-stage falciparum infection; it is used for transmission blocking and (in vivax/ovale) radical cure.
10. Two travelers visit the same malaria-endemic area for the same dates. One takes atovaquone-proguanil and the other takes mefloquine. Integrating the causal-versus-suppressive distinction with post-travel dosing, which statement correctly describes how long each must continue the drug after leaving?
A) Both must continue for four weeks after leaving, because all prophylactics act only on the blood stage
B) Both can stop on the day of departure, because leaving the area ends all risk immediately
C) The mefloquine traveler can stop on departure, while the atovaquone-proguanil traveler must continue four weeks
D) The atovaquone-proguanil traveler can stop about a week after leaving because that drug acts on the liver stage (causal), whereas the mefloquine traveler must continue about four weeks because mefloquine acts only on the blood stage (suppressive)
E) The required duration depends only on body weight, not on the drug's mechanism
ANSWER: D
Rationale:
This question integrates the causal-versus-suppressive distinction with practical post-travel dosing. Atovaquone-proguanil is a causal prophylactic that kills liver-stage parasites before blood infection is established, so it is continued only about a week after leaving the endemic area. Mefloquine is a suppressive prophylactic acting only on blood-stage parasites, so it must be continued about four weeks after departure to cover parasites emerging from the liver. This is correct.
Option A: Option A is incorrect because not all prophylactics act only on the blood stage; the causal agent acts on the liver stage and needs a shorter tail.
Option B: Option B is incorrect because parasites already acquired can still emerge after departure, so neither drug is simply stopped on the day of leaving.
Option C: Option C inverts the two regimens.
Option E: Option E is incorrect because the required post-travel duration is determined by the drug's mechanism (causal vs suppressive), not by body weight.
11. A patient treated for falciparum malaria becomes parasitemic again 21 days after starting therapy. Integrating the concept of treatment failure with resistance monitoring, how should this recurrence be interpreted and investigated?
A) It is automatically a new infection, because recurrence within a month always means reinfection
B) It is automatically drug failure, and no further investigation is useful
C) Recurrence within 28 days should be treated as recrudescence (true treatment failure) until proven otherwise, and molecular genotyping can distinguish recrudescence of the original parasite from a new infection (reinfection), which has different implications for drug efficacy
D) It indicates the patient has developed hypnozoite relapse, which is typical of falciparum
E) It proves the original diagnosis was incorrect
ANSWER: C
Rationale:
This question integrates the definition of treatment failure with resistance monitoring. Recurrent parasitemia within 28 days should be treated as recrudescence — survival and regrowth of the original infection, indicating drug failure — until proven otherwise. Molecular genotyping can distinguish recrudescence (same parasite genotype, implying drug failure) from reinfection (a new genotype, implying continued exposure rather than drug failure), and the distinction matters for assessing drug efficacy and resistance. This is correct.
Option A: Option A is incorrect because early recurrence is not automatically reinfection; recrudescence must be excluded.
Option B: Option B is incorrect because genotyping does add useful information by distinguishing failure from reinfection.
Option D: Option D is incorrect because falciparum does not form hypnozoites and does not cause true relapse; recurrence reflects recrudescence or reinfection, not dormant liver forms.
Option E: Option E is incorrect because early recurrence does not prove the original diagnosis was wrong.
12. A patient with systemic lupus erythematosus is started on long-term hydroxychloroquine. Although the indication is not malaria, the same pharmacology governs its toxicity. Integrating the mechanism of 4-aminoquinoline toxicity with chronic monitoring, which statement is correct?
A) No eye monitoring is needed, because hydroxychloroquine has no ocular toxicity
B) Hydroxychloroquine can cause cumulative, dose- and duration-dependent retinopathy, so a baseline ophthalmologic examination and periodic screening are indicated, and the daily dose is kept within a weight-based ceiling to limit risk
C) The main long-term risk is oxidative hemolysis, so serial G6PD testing replaces eye examinations
D) The main long-term risk is neuropsychiatric, so periodic psychiatric screening is the key monitoring step
E) Monitoring is unnecessary because the long half-life makes toxicity impossible
ANSWER: B
Rationale:
This question integrates the 4-aminoquinoline toxicity profile with chronic monitoring in a non-malarial setting. Chloroquine and hydroxychloroquine can cause cumulative, dose- and duration-dependent retinopathy that may be irreversible, so a baseline ophthalmologic examination and periodic retinal screening are indicated, and the daily dose is kept within a weight-based ceiling to limit risk. This is correct.
Option A: Option A is incorrect because hydroxychloroquine does have a recognized, monitored ocular toxicity.
Option C: Option C is incorrect because oxidative hemolysis in G6PD deficiency is the hallmark of the 8-aminoquinolines, not the principal chronic concern of hydroxychloroquine.
Option D: Option D is incorrect because the prominent neuropsychiatric toxicity belongs to mefloquine, not hydroxychloroquine.
Option E: Option E is incorrect because a long half-life does not eliminate toxicity; the long persistence actually contributes to the cumulative risk that monitoring is designed to detect.
13. In a setting where quinine is used to treat severe falciparum malaria, the clinician must design the regimen and anticipate a metabolic complication. Integrating regimen design with adverse-effect monitoring, which combined plan is correct?
A) Give quinine alone with no companion drug, and restrict glucose because quinine causes hyperglycemia
B) Give quinine with a companion antibiotic only if cinchonism develops, and monitor for hypertension
C) Give quinine as a single dose, and monitor for hyperkalemia as the principal metabolic risk
D) Give quinine with a companion antibiotic for 7 days, and monitor for hypernatremia
E) Pair quinine with a companion antibiotic (doxycycline or clindamycin) for a 7-day course to improve cure and limit resistance, and monitor blood glucose closely because quinine stimulates insulin secretion and the falciparum infection itself increases glucose consumption, predisposing to hypoglycemia
ANSWER: E
Rationale:
This question integrates regimen design with adverse-effect monitoring. Quinine is paired with a companion antibiotic (doxycycline or clindamycin) over a 7-day course to improve cure rates and limit resistance selection, and the patient must have blood glucose monitored because quinine stimulates pancreatic insulin secretion and severe falciparum infection increases glucose consumption, together predisposing to hypoglycemia. This is correct.
Option A: Option A is incorrect because quinine should not be given without a companion drug, and quinine causes hypoglycemia, not hyperglycemia, so glucose restriction would be harmful.
Option B: Option B is incorrect because the companion antibiotic is part of the planned regimen from the start, not a reaction to cinchonism, and the key metabolic risk is hypoglycemia, not hypertension.
Option C: Option C is incorrect because quinine is not given as a single dose for severe malaria and the principal metabolic risk is hypoglycemia, not hyperkalemia.
Option D: Option D is incorrect because, although it includes the companion antibiotic for 7 days, it names the wrong complication; the characteristic metabolic risk is hypoglycemia, not hypernatremia.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.